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A B S T R A C T
Objective: To describe a fatal case of influenza A pneumonia in a patient with severe lymphopenia after receiving
subcutaneous cladribine to treat her multiple sclerosis (MS).
Methods: Case report.
Results: A 53-year-old woman developed fatal influenza pneumonia associated with grade 4 lymphopenia two
months after receiving a total dose of 60mg subcutaneous cladribine. Despite treatment with oseltamivir, her
condition deteriorated and the patient passed away after developing respiratory failure.
Conclusion: Cladribine-related lymphopenia is usually mild to moderate, however severe lymphopenia may
occur. People with MS, especially those who are immunosuppressed, should be offered the inactivated influenza
vaccine annually.
1. Introduction
Cladribine is a synthetic purine nucleoside analogue originally de-
veloped as a treatment for haematologic malignancies. More recently,
an oral formulation of cladribine (Mavenclad®) has been licensed for
treating people with relapsing multiple sclerosis (pwRMS) [1]. We have
been using subcutaneously administered (s.c.) cladribine (Litak®) to
treat over 210 people with MS (pwMS) since November 2014 [2].
Whilst semi-selective lymphocyte depletion is considered key to the
efficacy of cladribine in controlling MS, lymphopenia also leads to
adverse risk, mainly of viral infections [3]. Although lymphopenia is
usually mild to moderate, a small number of pwMS develop severe
lymphopenia [4,5]. We report the case of a woman who developed
grade 4 lymphopenia in the context of cladribine treatment for her MS,
and died of influenza A pneumonia.
2. Case report
A 53-year-old woman with a 21-year history of RMS, was first di-
agnosed after an attack of lower limb weakness and numbness. Her only
other significant medical history was hypothyroidism. She initially had
a relatively mild course of the disease with no restriction in mobility.
However, 15 years after disease onset she suffered a severe relapse
associated with a new cervical lesion that left her with an Expanded
Disability Status Scale (EDSS) score of 9.5. Treatment with natalizumab
was started and although she gradually recovered over the following
month, her new baseline EDSS score stabilised at 8.5. Eight months into
the treatment she became seropositive for JC virus. Whilst her antibody
titre remained below 0.9 for 5 years, it then increased up to 1.34. After
discussing the risks of no treatment, for example rebound disease ac-
tivity on natalizumab withdrawal, a decision was made to switch onto a
different immunotherapy. Safety checks were successfully addressed
and she was started on s.c. cladribine using a treatment schedule de-
veloped in-house [6]. At baseline, white blood cell count (WBC) was
8.5x109/L (normal, 4-11x109/L) and total lymphocyte count (TLC) was
3.6x109/L (normal, 1-4.8x109/L). In week 1 she received cladribine
10mg s.c. on three consecutive days. TLC at week 4 was 1.9x109/L, and
she was given another 10mg of s.c. cladribine on three consecutive days
in week 5. At week 6 her TLC was 1.1x109/L. At week 13, she presented
to the emergency room with new onset dyspnoea. Her blood pressure
was 96/57 mm Hg, pulse rate 81 bpm, respiratory rate 21/min and
temperature 35,7°C. Peripheral oxygen saturation was 95% with a FiO2
of 0.5. Crackles were noted in both lower lung fields. Neurological
examination showed no new findings compared to her baseline. Blood
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tests revealed grade 4 lymphopenia with a TLC of 0.2x109/L. WBC was
4.2x109/L with 0.1x109/L monocytes and 3.9x109/L neutrophils. The
time course of her WBC and TLC is shown in Fig.1. Her haemoglobin
concentration was 88g/L and platelet count 120x109/L. Her C-reactive
protein was 182 mg/L. Chest X-ray revealed patchy opacification
within the right lower zone suggesting pneumonia, and treatment with
amoxicillin and clarithromycin was started. Influenza A virus target
RNA was detected from a nose swab and treatment with oseltamivir
was initiated. However, she gradually deteriorated and five days after
admission she developed progressive respiratory failure and died. Since
influenza vaccination would have coincided with the start of her im-
munotherapy, she did not receive her seasonal influenza vaccine.
3. Discussion
Cladribine has been shown to be a relatively safe and effective form
of therapy for RMS [4]. Its mechanism of benefit is not fully understood
but the most striking effect appears to be semi-selective, and relatively
long-lasting, depletion of B and T lymphocytes with a particularly sig-
nificant and long-lasting reduction for memory B cells [3]. Hence,
lymphopenia is a regular observation in people treated with cladribine
that relates to both its therapeutic mechanism of action as well as the
potential associated risk, particularly viral infections or reactivations,
such as shingles [3].
A previous study on pwRMS receiving s.c. cladribine reported a
decrease of the mean TLC of approximately 40–45% compared to
baseline [7]. The medication was administered monthly for six months,
and an additional injection was given three months later. TLC reached a
nadir approximately six months after treatment initiation with counts
recovering thereafter, and no cases of grade 3 or grade 4 lymphopenia
occurred [7]. Bearing in mind differences in the dosing schedule be-
tween studies, these results are comparable with data from our centre
where only 2% of patients developed grade 3 lymphopenia [2]. How-
ever, the case presented here is a cautionary tale that grade 4 lym-
phopenia can occur even after following a personalised dosing protocol
designed to prevent severe lymphopenia [6]. Another factor that could
have contributed to lymphopenia in our patient is the influenza virus
infection. However, grade 4 lymphopenia such as the one experienced
by our patient is rare in otherwise immunocompetent patients with
influenza virus infection [8,9].
Two large trials of oral cladribine in pwRMS and patients with a first
clinical demyelinating event (CLARITY and ORACLE MS, respectively)
evaluated the clinical effectiveness and safety profile of oral cladribine
tablets [4,5]. In both studies, most of the lymphopenia events were
classified as mild or moderate and occurred more frequently with
higher doses. The CLARITY extension study confirmed these findings
[10]. Additionally, a post-hoc analysis of the CLARITY and CLARITY
extension studies showed no cases of grade 4 lymphopenia in pwRMS
treated with cladribine tablets 3.5 mg/kg using a dosing schedule that
took into account the TLC (i.e. Grade 0 lymphocyte count at the start of
treatment and a maximum of grade 1 at the start of the second cycle)
[10].
The WHO recommends that people who are most at risk of devel-
oping serious complications from influenza infection be vaccinated
every year before the season begins. Clinical risk groups who should
receive the influenza immunisation include adults with chronic neu-
rological conditions, such as MS, and/or those who are im-
munosuppressed due to disease or treatment [11]. The patient reported
here started immune reconstitution treatment with cladribine at a time
when her seasonal influenza vaccination was due, and a decision was
made to delay her immunisation. Whilst the inactivated influenza
vaccine can generally be considered safe at any point of treatment, it
will remain unclear whether this patient would have mounted an ef-
fective immune response during TLC depletion. Recent data suggest
that the inactivated influenza vaccine will still provide some protection
in patients already receiving B cell depletion therapy [12]. However,
the vaccination response during lymphocyte depletion in pwMS treated
with cladribine is uncertain and should be studied in a formal research
protocol. The live attenuated influenza vaccine is given as a nasal spray
and is contraindicated in people who are clinically severely im-
munocompromised and in their close contacts [11,13]. Cladribine
treatment should not be initiated within four weeks after vaccination
with an attenuated live vaccine and pwMS treated with cladribine
should not receive live vaccines until their WBC and TLC have returned
to within their normal reference ranges [14]. In line with WHO gui-
dance and the UK national influenza immunisation programme [11,13],
we recommend annual influenza vaccination with inactivated, but not
live vaccines, in pwMS who have received cladribine and whose im-
mune system is compromised. Nevertheless, inactivated vaccines
should ideally be administered at least two weeks before commencing
immunosuppressive treatments [13]. Influenza immunisation should
also be recommended for household members and carers of pwMS, as
well as healthcare and social care workers in direct contact with pwMS
[13].
4. Conclusion
We report a case of lethal influenza A infection associated with
grade 4 lymphopenia in an MS patient receiving s.c. cladribine. This
incident occurred despite using a personalised dosing schedule that was
adapted to both body weight and individual TLC. Influenza vaccination
may de-risk the use of cladribine further. As some im-
munocompromised patients may have a suboptimal immunological
response to the vaccine, the inactivated influenza vaccine should
Fig. 1. White blood cells and lymphocytes counts.
Baseline white blood cells (1A) and lymphocytes (1B) counts at week 6 of treatment with cladribine and its course after hospital admission in week 13. LC:
lymphocyte count. WBC: white blood cell. W6: week 6. W13: week 13.
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ideally be administered prior to treatment initiation with cladribine.
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